Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Amortization of Deferred Charges (2019 - 2021)

Utah Medical Products (UTMD) has 3 years of Amortization of Deferred Charges data on record, last reported at $11000.0 in Q3 2021.

  • For Q3 2021, Amortization of Deferred Charges rose 10.0% year-over-year to $11000.0; the TTM value through Sep 2021 reached $42000.0, up 10.53%, while the annual FY2020 figure was $39000.0, 2.63% up from the prior year.
  • Amortization of Deferred Charges reached $11000.0 in Q3 2021 per UTMD's latest filing, roughly flat from $11000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $11000.0 in Q2 2021 and bottomed at $9000.0 in Q2 2019.
  • Average Amortization of Deferred Charges over 3 years is $9909.1, with a median of $10000.0 recorded in 2019.
  • The widest YoY moves for Amortization of Deferred Charges: up 11.11% in 2020, down 10.0% in 2020.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $9000.0 in 2019, then grew by 11.11% to $10000.0 in 2020, then grew by 10.0% to $11000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $11000.0 in Q3 2021, $11000.0 in Q2 2021, and $10000.0 in Q1 2021.